MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results for Sonelokimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Results: MoonLake Immunotherapeutics announced that in its Phase 3 VELA-1 and VELA-2 trials, 67.2% of patients treated with Sonelokimab achieved HiSCR75 at Week 52, indicating significant efficacy in treating moderate-to-severe hidradenitis suppurativa, which could enhance the company's market share in this area.
- Consistent Safety Profile: The safety profile of Sonelokimab in the VELA clinical programs remained stable over time with no new safety signals detected, providing confidence for future regulatory approvals and potentially accelerating the FDA review process.
- Upcoming Milestones: The company expects to submit a Biologics License Application (BLA) for Sonelokimab by the end of September 2026, and plans to release primary endpoint data from the Phase 3 IZAR-2 trial in PsA in the second half of 2026, laying the groundwork for future product line expansion.
- Investor Day Event: MoonLake is hosting an investor day webcast today to discuss clinical data and guidance on upcoming events, which is expected to attract investor interest and further enhance the company's image in the capital markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 19.150
Low
5.00
Averages
24.10
High
45.00
Current: 19.150
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CFO Sells 39,120 Shares of MoonLake Immunotherapeutics
- Executive Share Sale: Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, sold 39,120 common shares on June 22 for approximately $862,000, indicating potential concerns about executive confidence in the company's future prospects.
- Ownership Proportion: The sale represented 3.4% of Bodenstedt's direct holdings, leaving him with over 1.1 million shares post-transaction, which suggests a significant investment remains, yet the sale may raise market apprehensions.
- Market Sensitivity: MoonLake's stock experienced extreme volatility, plummeting from over $60 to about $6 in late September, highlighting the market's sensitivity to product development news, especially as the company currently lacks government-approved products, leading to revenue uncertainty.
- Transaction Transparency: Both Bodenstedt and CEO Jorge Santos da Silva executed their sales through 10b5-1 trading plans, designed to mitigate insider trading concerns; however, investors should remain cautious regarding the company's future profitability.
See More
MoonLake CFO Sells Shares Amid Market Volatility
- Executive Share Sale: Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, sold 39,120 common shares on June 22 for approximately $862,000, representing 3.4% of his direct holdings, indicating a cautious stance from executives amid market uncertainty.
- Remaining Holdings: Post-transaction, Bodenstedt retains 1,115,435 Class A ordinary shares, suggesting some level of confidence in the company, yet the sale may raise concerns about the company's future prospects among investors.
- Market Volatility: MoonLake's stock price plummeted from over $60 to about $6 in late September, primarily due to disappointing study results, highlighting the high-risk nature of the company's product development efforts.
- Investor Caution: Although the share sales were executed under 10b5-1 trading plans to mitigate insider trading concerns, MoonLake lacks any approved products and revenue generation, necessitating careful risk assessment by potential investors.
See More
MoonLake Immunotherapeutics Shares Drop Amid Secondary Offering
- Stock Price Decline: MoonLake Immunotherapeutics saw its shares drop nearly 6% on Wednesday due to the announcement of a secondary stock offering, which negatively impacted investor sentiment and market confidence.
- Funding Plan: The company announced the pricing of 9 million Class A ordinary shares at $20 each, expecting to raise between $180 million and $200 million, exceeding its previous target of $150 million, highlighting the urgency of its funding needs.
- R&D Investment: The funds raised will be allocated to continue research, pre-commercialization, and commercialization activities for its leading drug candidate, sonelokimab, indicating a strategic focus on treating multiple autoimmune conditions.
- Dilution Effect: This offering will dilute the existing 74.6 million shares outstanding, and while investors typically react negatively to dilution, management's pursuit of capital to support sonelokimab's development reflects confidence in future market opportunities.
See More
MoonLake Aims to Raise $200 Million to Support Drug Development
- Funding Target: MoonLake Immunotherapeutics plans to raise between $180 million and $200 million by floating 9 million Class A ordinary shares at $20 each, aimed at supporting the research and commercialization of its leading drug candidate, sonelokimab.
- Dilution Impact: The new share issuance will dilute the existing 74.6 million shares outstanding, and while investors typically react negatively to dilution, seeking fresh funding is a common practice in the biotech sector, especially during late-stage drug development.
- Market Reaction: Following the announcement of the secondary offering, MoonLake's stock fell nearly 6% during the trading session, indicating negative investor sentiment towards the new share issuance, despite management's proactive approach to secure funding for critical drug development.
- Use of Proceeds: The funds raised will be allocated to research, pre-commercialization, and commercialization activities for sonelokimab, underscoring the company's confidence in the drug's potential across multiple autoimmune indications.
See More
MoonLake Immunotherapeutics Upsizes Offering to $200 Million Amid Strong Phase 3 Data
- Offering Details: MoonLake Immunotherapeutics is pricing its upsized public offering at $19.99 per share, representing a 5.7% discount to Tuesday's closing price, aiming to raise $200 million to fund the research and potential commercialization of Sonelokimab, indicating strong confidence in future market opportunities.
- Strong Clinical Results: The company reported that approximately two-thirds of patients in its Phase 3 trial achieved at least a 75% reduction in painful abscesses, with about 25% achieving complete inflammatory remission, showcasing the therapy's efficacy and favorable safety profile over one year.
- Market Sentiment: Despite the stock drifting lower in pre-market trading following the strong clinical data release, retail sentiment on Stocktwits shifted to 'extremely bullish', reflecting optimism about the company's future potential and the offering's strategic rationale to extend cash runway without incurring debt.
- Regulatory Filing Plans: MoonLake plans to file for regulatory approval for Sonelokimab by the end of September, which, if successful, could significantly enhance its competitive position in the inflammatory skin and joint disease market, potentially leading to substantial commercial returns.
See More
MoonLake Immunotherapeutics Prices $200M Public Offering
- Public Offering Pricing: MoonLake Immunotherapeutics has successfully priced an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share, with expected gross proceeds of approximately $200 million, reflecting strong market confidence in its capital needs.
- Pre-Funded Warrants Issuance: The offering includes pre-funded warrants that are immediately exercisable, allowing for the purchase of up to 1 million additional shares, providing the company with flexible financing options to support its development projects.
- Clear Use of Proceeds: MoonLake intends to utilize the net proceeds for research, development, and commercialization activities of sonelokimab, which, if approved, will enhance the company's competitive position in the biotechnology sector.
- Strategic Growth Direction: This public offering not only strengthens MoonLake's capital base but also ensures necessary funding for future product launches and overall corporate operations, demonstrating its proactive approach to seizing market opportunities.
See More
CFO Sells 39,120 Shares of MoonLake Immunotherapeutics
- Executive Share Sale: Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, sold 39,120 common shares on June 22 for approximately $862,000, indicating potential concerns about executive confidence in the company's future prospects.
- Ownership Proportion: The sale represented 3.4% of Bodenstedt's direct holdings, leaving him with over 1.1 million shares post-transaction, which suggests a significant investment remains, yet the sale may raise market apprehensions.
- Market Sensitivity: MoonLake's stock experienced extreme volatility, plummeting from over $60 to about $6 in late September, highlighting the market's sensitivity to product development news, especially as the company currently lacks government-approved products, leading to revenue uncertainty.
- Transaction Transparency: Both Bodenstedt and CEO Jorge Santos da Silva executed their sales through 10b5-1 trading plans, designed to mitigate insider trading concerns; however, investors should remain cautious regarding the company's future profitability.
See More
MoonLake CFO Sells Shares Amid Market Volatility
- Executive Share Sale: Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, sold 39,120 common shares on June 22 for approximately $862,000, representing 3.4% of his direct holdings, indicating a cautious stance from executives amid market uncertainty.
- Remaining Holdings: Post-transaction, Bodenstedt retains 1,115,435 Class A ordinary shares, suggesting some level of confidence in the company, yet the sale may raise concerns about the company's future prospects among investors.
- Market Volatility: MoonLake's stock price plummeted from over $60 to about $6 in late September, primarily due to disappointing study results, highlighting the high-risk nature of the company's product development efforts.
- Investor Caution: Although the share sales were executed under 10b5-1 trading plans to mitigate insider trading concerns, MoonLake lacks any approved products and revenue generation, necessitating careful risk assessment by potential investors.
See More
MoonLake Immunotherapeutics Shares Drop Amid Secondary Offering
- Stock Price Decline: MoonLake Immunotherapeutics saw its shares drop nearly 6% on Wednesday due to the announcement of a secondary stock offering, which negatively impacted investor sentiment and market confidence.
- Funding Plan: The company announced the pricing of 9 million Class A ordinary shares at $20 each, expecting to raise between $180 million and $200 million, exceeding its previous target of $150 million, highlighting the urgency of its funding needs.
- R&D Investment: The funds raised will be allocated to continue research, pre-commercialization, and commercialization activities for its leading drug candidate, sonelokimab, indicating a strategic focus on treating multiple autoimmune conditions.
- Dilution Effect: This offering will dilute the existing 74.6 million shares outstanding, and while investors typically react negatively to dilution, management's pursuit of capital to support sonelokimab's development reflects confidence in future market opportunities.
See More
MoonLake Aims to Raise $200 Million to Support Drug Development
- Funding Target: MoonLake Immunotherapeutics plans to raise between $180 million and $200 million by floating 9 million Class A ordinary shares at $20 each, aimed at supporting the research and commercialization of its leading drug candidate, sonelokimab.
- Dilution Impact: The new share issuance will dilute the existing 74.6 million shares outstanding, and while investors typically react negatively to dilution, seeking fresh funding is a common practice in the biotech sector, especially during late-stage drug development.
- Market Reaction: Following the announcement of the secondary offering, MoonLake's stock fell nearly 6% during the trading session, indicating negative investor sentiment towards the new share issuance, despite management's proactive approach to secure funding for critical drug development.
- Use of Proceeds: The funds raised will be allocated to research, pre-commercialization, and commercialization activities for sonelokimab, underscoring the company's confidence in the drug's potential across multiple autoimmune indications.
See More
MoonLake Immunotherapeutics Upsizes Offering to $200 Million Amid Strong Phase 3 Data
- Offering Details: MoonLake Immunotherapeutics is pricing its upsized public offering at $19.99 per share, representing a 5.7% discount to Tuesday's closing price, aiming to raise $200 million to fund the research and potential commercialization of Sonelokimab, indicating strong confidence in future market opportunities.
- Strong Clinical Results: The company reported that approximately two-thirds of patients in its Phase 3 trial achieved at least a 75% reduction in painful abscesses, with about 25% achieving complete inflammatory remission, showcasing the therapy's efficacy and favorable safety profile over one year.
- Market Sentiment: Despite the stock drifting lower in pre-market trading following the strong clinical data release, retail sentiment on Stocktwits shifted to 'extremely bullish', reflecting optimism about the company's future potential and the offering's strategic rationale to extend cash runway without incurring debt.
- Regulatory Filing Plans: MoonLake plans to file for regulatory approval for Sonelokimab by the end of September, which, if successful, could significantly enhance its competitive position in the inflammatory skin and joint disease market, potentially leading to substantial commercial returns.
See More
MoonLake Immunotherapeutics Prices $200M Public Offering
- Public Offering Pricing: MoonLake Immunotherapeutics has successfully priced an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share, with expected gross proceeds of approximately $200 million, reflecting strong market confidence in its capital needs.
- Pre-Funded Warrants Issuance: The offering includes pre-funded warrants that are immediately exercisable, allowing for the purchase of up to 1 million additional shares, providing the company with flexible financing options to support its development projects.
- Clear Use of Proceeds: MoonLake intends to utilize the net proceeds for research, development, and commercialization activities of sonelokimab, which, if approved, will enhance the company's competitive position in the biotechnology sector.
- Strategic Growth Direction: This public offering not only strengthens MoonLake's capital base but also ensures necessary funding for future product launches and overall corporate operations, demonstrating its proactive approach to seizing market opportunities.
See More
